ArticleClinical drug investigation2023

Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.

Andrew Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.